Our history

The Prague-based biotechnological start-up Elphogene, Inc. has received an initial investment from i&i Prague in order to implement its oncoMonitor™, a liquid biopsy technology into a commercial assay for non-invasive diagnostic monitoring of patients in advanced stages colorectal cancer.

The company has been founded at the beginning of 2019 as a spin-off from the Genomac Research Institute, a leading Czech private research center widely recognized for its strong record of scientific projects in clinical cancer genomics.

Originally developed at Genomac and now exclusively owned by Elphogene, the oncoMonitor™ liquid biopsy technology, will further be developed and validated in a clinical setting at company headquarters and laboratories located near Prague Vaclav Havel airport in Ruzyne.